Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

Women are increasingly taking the lead at grand rounds, however, female grand lecturers are still markedly underrepresented ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

Texas Children's Hospital and Baylor College of Medicine are providing medication and other aid to fight sickle cell disease ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Lotte Biologics has ambitious plans for its antibody-drug conjugate and contract development and manufacturing organization ...

Analysts at Leerink Partnrs boosted their Q4 2024 EPS estimates for Bristol-Myers Squibb in a report released on Sunday, ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on 'Advancing as a Global CDMO Leader' ...

Compared with AS alone, coexisting ATTR-CA was associated with an increased risk of mortality (HR 1.3, 95% CI 1.1-1.4) in a ...